Lonza, a CDMO focused on bioconjugates, has announced an expansion to its site in Visp, Switzerland, doubling its capacity for the manufacture and commercial supply of bioconjugates.

The existing facility will gain two 1200L manufacturing suites and infrastructure occupying an additional 2000 square metres. By 2028 it is expected that the project will double Lonza’s production capacity.

This supports the company’s recent announcement to address the growing demand for bioconjugation products, and will include manufacturing for early phase clinical development, drug product filling capacity and large-scale commercial supply.